{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pemetrexed+%28Chemotherapy%29&page=4", "query": { "intervention": "Pemetrexed (Chemotherapy)", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 381, "total_pages": 39, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pemetrexed+%28Chemotherapy%29&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pemetrexed+%28Chemotherapy%29&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T03:34:57.886Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03520686", "title": "Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "NAI + Pembrolizumab", "type": "DRUG" }, { "name": "NAI + Nivolumab + Ipilimumab", "type": "DRUG" }, { "name": "NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel", "type": "DRUG" }, { "name": "Cisplatin/Carboplatin + Pemetrexed + Pembrolizumab + NAI", "type": "DRUG" }, { "name": "Cisplatin/Carboplatin + Pemetrexed + Atezolizumab + NAI", "type": "DRUG" }, { "name": "Carboplatin + Paclitaxel + Atezolizumab + Bevacizumab + NAI", "type": "DRUG" }, { "name": "Carboplatin + Nab-paclitaxel + Atezolizumab + NAI", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel", "type": "DRUG" }, { "name": "Drug: Cisplatin/Carboplatin and Pemetrexed plus Pembrolizumab", "type": "DRUG" }, { "name": "Cisplatin/Carboplatin and Pemetrexed plus Atezolizumab", "type": "DRUG" }, { "name": "Carboplatin and Paclitaxel plus Atezolizumab and Bevacizumab", "type": "DRUG" }, { "name": "Carboplatin and Nab-paclitaxel plus Atezolizumab", "type": "DRUG" }, { "name": "Nogapendekin alfa inbakicept (NAI) + Nivolumab + Ipilimumab + Carboplatin + Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 102, "start_date": "2018-05-18", "completion_date": "2025-10-13", "has_results": false, "last_update_posted_date": "2026-05-26", "last_synced_at": "2026-10-14T03:34:57.886Z", "location_count": 31, "location_summary": "Anchorage, Alaska • Hot Springs, Arkansas • El Segundo, California + 28 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "El Segundo", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03520686" }, { "nct_id": "NCT06996782", "title": "A Platform Study in Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced or Metastatic Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Rilvegostomig", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Ramucirumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 152, "start_date": "2025-11-24", "completion_date": "2029-02-23", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-14T03:34:57.886Z", "location_count": 10, "location_summary": "Phoenix, Arizona • Santa Rosa, California • Jacksonville, Florida + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06996782" }, { "nct_id": "NCT04035486", "title": "A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Osimertinib", "type": "DRUG" }, { "name": "Pemetrexed/Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed/Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "110 Years", "sex": "ALL", "summary": "18 Years to 110 Years" }, "enrollment_count": 587, "start_date": "2019-07-02", "completion_date": "2027-09-30", "has_results": true, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-10-14T03:34:57.886Z", "location_count": 23, "location_summary": "Bellflower, California • Fullerton, California • La Jolla, California + 19 more", "locations": [ { "city": "Bellflower", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Santa Rosa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04035486" }, { "nct_id": "NCT00828841", "title": "Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Cetuximab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Accelerated Community Oncology Research Network", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 601, "start_date": "2008-12", "completion_date": "2012-08", "has_results": true, "last_update_posted_date": "2013-11-06", "last_synced_at": "2026-10-14T03:34:57.886Z", "location_count": 84, "location_summary": "Anniston, Alabama • Jonesboro, Arkansas • Anaheim, California + 81 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Azusa", "state": "California" }, { "city": "Burbank", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00828841" }, { "nct_id": "NCT02707666", "title": "A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pleural Mesothelioma" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Cisplatin and Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2016-02-25", "completion_date": "2023-04-24", "has_results": false, "last_update_posted_date": "2024-07-31", "last_synced_at": "2026-10-14T03:34:57.886Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02707666" }, { "nct_id": "NCT03003962", "title": "Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non Small Cell Lung Carcinoma NSCLC" ], "interventions": [ { "name": "Durvalumab (MEDI4736)", "type": "DRUG" }, { "name": "Paclitaxel + carboplatin", "type": "DRUG" }, { "name": "Gemcitabine + cisplatin", "type": "DRUG" }, { "name": "Gemcitabine + carboplatin", "type": "DRUG" }, { "name": "Pemetrexed + cisplatin", "type": "DRUG" }, { "name": "Pemetrexed + carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 669, "start_date": "2017-01-02", "completion_date": "2026-06-30", "has_results": true, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-10-14T03:34:57.886Z", "location_count": 1, "location_summary": "Anaheim, California", "locations": [ { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03003962" }, { "nct_id": "NCT04105270", "title": "RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of Lung", "Lung Cancer" ], "interventions": [ { "name": "Oral Restorative Microbiota Therapy (RMT) Capsules", "type": "DRUG" }, { "name": "Durvalumab 1500 mg IV", "type": "DRUG" }, { "name": "Cisplatin/pemetrexed or Carboplatin/pemetrexed", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 82, "start_date": "2022-11-30", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-10-14T03:34:57.886Z", "location_count": 10, "location_summary": "Phoenix, Arizona • Brainerd, Minnesota • Deer River, Minnesota + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Brainerd", "state": "Minnesota" }, { "city": "Deer River", "state": "Minnesota" }, { "city": "Detroit Lakes", "state": "Minnesota" }, { "city": "Duluth", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04105270" }, { "nct_id": "NCT01098266", "title": "NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Malignant Pleural Mesothelioma" ], "interventions": [ { "name": "NGR-hTNF plus Best Investigator's Choice (BIC)", "type": "DRUG" }, { "name": "Placebo plus Best Investigator's Choice (BIC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AGC Biologics S.p.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2010-04-12", "completion_date": "2017-12", "has_results": true, "last_update_posted_date": "2019-09-17", "last_synced_at": "2026-10-14T03:34:57.886Z", "location_count": 7, "location_summary": "Corona, California • Duarte, California • Tampa, Florida + 4 more", "locations": [ { "city": "Corona", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01098266" }, { "nct_id": "NCT03064854", "title": "PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "PDR001", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Canakinumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 111, "start_date": "2017-05-24", "completion_date": "2021-07-28", "has_results": false, "last_update_posted_date": "2022-08-15", "last_synced_at": "2026-10-14T03:34:57.886Z", "location_count": 5, "location_summary": "Fayetteville, Arkansas • Santa Monica, California • Stanford, California + 2 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Santa Monica", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03064854" }, { "nct_id": "NCT04297605", "title": "Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Pemetrexed (Chemotherapy)", "type": "OTHER" }, { "name": "Nab-paclitaxel (Chemotherapy)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2020-05-15", "completion_date": "2028-01-30", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-10-14T03:34:57.886Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04297605" } ] }